Evidence map›Paper›PMID 21234334›Full record

ArticleStem cells international2010

Mesenchymal Progenitor Cells and Their Orthopedic Applications: Forging a Path towards Clinical Trials.

Deana S Shenaq, Farbod Rastegar, Djuro Petkovic, Bing-Qiang Zhang, Bai-Cheng He, Liang Chen, Guo-Wei Zuo, Qing Luo, Qiong Shi, Eric R Wagner and 15 more

Open access · goldAbstract read
In one paragraph

Article in Stem cells international, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Trauma and Stem Cells: Biology and Potential Therapeutic Implications.International journal of molecular sciences · 2017
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 2 countries.

Deana S ShenaqMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, 5841 South Maryland Avenue, MC3079, Chicago, IL 60637, USA.
Farbod Rastegar
Djuro Petkovic
Bing-Qiang Zhang
Bai-Cheng He
Liang Chen
Guo-Wei Zuo
Qing Luo
Qiong Shi
Eric R Wagner
Enyi Huang
Yanhong Gao
Jian-Li Gao
Stephanie H Kim
Ke Yang
Yang Bi
Yuxi Su
Gaohui Zhu
Jinyong Luo
Xiaoji Luo
Jiaqiang Qin
Russell R Reid
Hue H Luu
Rex C Haydon
Tong-Chuan He
University of Chicago Medical Center · USMolecular Oncology (United States) · USChildren's Hospital of Chongqing Medical University · CNChongqing Medical University · CNArmy Medical University · CN

Funding

Regulation of beta-Catenin Signaling by Tyrosine PhosphorylationR01CA106569 · NCI · UNIVERSITY OF CHICAGO · PI HE, TONG-CHUAN · 2006 to 2010
$1.3M
BMP6-Mediated OsteogenesisK08AR050142 · NIAMS · UNIVERSITY OF CHICAGO · PI HAYDON, REX C · 2004 to 2008
$596k
The role of connective Tissue Growth Factor on BMP9-Induced OsteogenesisK08AR054381 · NIAMS · UNIVERSITY OF CHICAGO · PI LUU, HUE HAN · 2007 to 2011
$595k
NCI NIH HHS R01 CA106569NIAMS NIH HHS K08 AR050142NIAMS NIH HHS K08 AR054381
6 · The paper itself

Abstract

Mesenchymal progenitor cells (MPCs) are nonhematopoietic multipotent cells capable of differentiating into mesenchymal and nonmesenchymal lineages. While they can be isolated from various tissues, MPCs isolated from the bone marrow are best characterized. These cells represent a subset of bone marrow stromal cells (BMSCs) which, in addition to their differentiation potential, are critical in supporting proliferation and differentiation of hematopoietic cells. They are of clinical interest because they can be easily isolated from bone marrow aspirates and expanded in vitro with minimal donor site morbidity. The BMSCs are also capable of altering disease pathophysiology by secreting modulating factors in a paracrine manner. Thus, engineering such cells to maximize therapeutic potential has been the focus of cell/gene therapy to date. Here, we discuss the path towards the development of clinical trials utilizing BMSCs for orthopaedic applications. Specifically, we will review the use of BMSCs in repairing critical-sized defects, fracture nonunions, cartilage and tendon injuries, as well as in metabolic bone diseases and osteonecrosis. A review of www.ClinicalTrials.gov of the United States National Institute of Health was performed, and ongoing clinical trials will be discussed in addition to the sentinel preclinical studies that paved the way for human investigations.

Identifiers

PMID21234334
PMCPMC3017936
OpenAlexW2145305383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.